MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
Exelixis, Inc. (NASDAQ: EXEL)*
Organization & Developments: Exelixis
Parents
Exelixis, Inc. (NASDAQ: EXEL)*
Children
*Genomics-based drug discovery
2018: Exelixis Blows Away Expectations_seekingalpha.com
2018: Exelixis: Cabozantinib Shows Better Efficacy Profile Than Competition - Exelixis, Inc. (NASDAQ:EXEL)
2018: Exelixis: Continued Upside In 2018 - Exelixis, Inc. (NASDAQ:EXEL)
2018: Exelixis: Going, Going, Gone_seekingalpha.com
2018: Exelixis: Our Latest Take On This Oncology Concern - Exelixis, Inc. (NASDAQ:EXEL)
2018: Exelixis: Time To Excel - Exelixis, Inc. (NASDAQ:EXEL)
2018: Results from late-stage study of Exelixis' Cabometyx in liver cancer published in NEJM_seekingalpha.com
2018: What's Wrong With Exelixis?_seekingalpha.com
2019: Exelixis Does It Again_seekingalpha.com
2019: Exelixis FDA Approval Opens Market Opportunity, But Challenge Remains_seekingalpha.com
2019: Exelixis_Targeting A 20% Return On A Mid-Cap Oncology _gallery.mailchimp.com
2019: Exelixis: Mid-Cap Oncology Concern Continues To Deliver Growth_seekingalpha.com
2019: Exelixis: Treatment Paradigm Winds See Cabometyx Falling Flat, For Now_seekingalpha.com
2020: Cabo/Opdivo Combo Unlikely To Move Needle, But Exelixis Remains Attractive
2020: Exelixis: Defying Corona Bear Market Expectations
2020: With new data, Exelixis takes another shot at prostate cancer treatment
2021: Exelixis: A Look At Its Potential
2021: In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer
2022: Exelixis, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Exelixis: Efforts Continue To Diversify The Pipeline_seekingalpha.com
2022: Exelixis: Undervalued And Unloved_ seekingalpha.com
2022: Exelixis/Roche Combo Fails to Improve Overall Survival in NSCLC_ biospace
2023: Exelixis: If It Ain't Broke..._ seekingalpha.com
2024: Exelixis Comes Up Aces
2024: Exelixis lays off 175 employees in refocus on ‘emerging pipeline’
2024: Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials
2024: Exelixis stock rises as key drug Cabometyx withstands patent challenge
2024: Exelixis: 2024 Looking Good In The Mid-Term_ seekingalpha.com
2024: Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles_seekingalpha
2024: Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
2024: Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 202
2024: Exelixis: sNDA Cabometyx Expansion Could Provide Revenue Boost_ seekingalpha.com
2024: Merck and Exelixis partner to evaluate new cancer combination treatments
2025: Exelixis: A Notable Quarter
2025: Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza_ seekingalpha.com
2025: Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow_ seekingalpha.com
2025: Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade)
2025: Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts
Organization & Developments: Exelixis (Archives 2010-2017)
Jumps
*Key People: Exelixis
Finance & Acquisition: Exelixis